Skip to content

Investor Relations / SEC Filings

SEC Filings

Filing date Form Filer Description View
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML EX-101.INS - XBRL INSTANCE DOCUMENT
8-K

Report of unscheduled material events or corporate event

View HTML
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

View HTML
PRE 14A

A preliminary proxy statement providing notification matters to be brought to a vote

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
4 KENNEDY JOSEPH T

Statement of changes in beneficial ownership of securities

View HTML
4 Ketchum Steven B

Statement of changes in beneficial ownership of securities

View HTML
4 THERO JOHN F

Statement of changes in beneficial ownership of securities

View HTML
3 Berg Aaron

Initial filing by director officer or owner of more than ten percent.

View HTML
4 Ekman Lars

Statement of changes in beneficial ownership of securities

View HTML

Copyright Morningstar

copyright
© 2019, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation